AUG 10, 2026 · JOURNAL ARTICLE
Comparison of Tailor X and NSABP-20 regarding cost-effectiveness of recurrence score (RS®) for adjuvant chemotherapy decision in early-stage breast cancer
BMC Health Services Research
A retrospective cost-effectiveness analysis in a single-centre Turkish cohort that confirms ODX RS reduces unnecessary chemotherapy and improves cost-effectiveness compared to clinicopathological assessment alone, consistent with TAILORx trial findings but without new primary efficacy data.
Reported
Unnecessary chemotherapy under NS…18 patients (~20%)
Cost-effectiveness gain (ICER) vs…at least $1938
QALYs gained0.68